This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Y-mAbs Therapeutics Tidigare resultatutveckling
Tidigare kriterier kontrolleras 0/6
Y-mAbs Therapeutics har ökat intäkterna med en genomsnittlig årlig takt på 29.4%, medan Biotechs -branschen såg intäkterna växande på 36.2% årligen. Intäkterna har varit växande med en genomsnittlig takt på 32.2% per år.
Viktig information
29.40%
Tillväxttakt i vinsten
31.88%
Tillväxttakt för EPS
| Biotechs Tillväxt i branschen | 17.04% |
| Intäkternas tillväxttakt | 32.18% |
| Avkastning på eget kapital | -25.40% |
| Nettomarginal | -26.03% |
| Senaste uppdateringen av resultatet | 30 Jun 2025 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Seeking Alpha • Aug 06
Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A
Summary Y-mAbs Therapeutics announced that it would be acquired at a >100% premium relative to recent trading. The deal showcases how little optimism there is in the biotech market at this time, even though recent investors are seeing substantial gains. This article lays out what SERB is going to get, and what I feel this transaction means for near-term biotech M&A. Read the full article on Seeking Alpha
Uppdatering av berättelse • Aug 06
Pipeline Developments And Radiopharmaceutical Advances Will Extend Global Reach
Despite improved profitability—with net profit margin rising to 12.26% and a lower future P/E of 47.56x—analysts have cut Y-mAbs Therapeutics’ consensus price target from $14.70 to $11.68, suggesting tempered growth expectations. What's in the News SERB S.A.S. agreed to acquire Y-mAbs Therapeutics for approximately $398.67 million ($8.6 per share); deal approved by Y-mAbs board and expected to close by December 31, 2025, subject to antitrust approval.Analysartikel • May 16
Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
A week ago, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) came out with a strong set of first-quarter numbers that could...Analysartikel • Apr 29
Insufficient Growth At Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Hampers Share Price
Y-mAbs Therapeutics, Inc.'s ( NASDAQ:YMAB ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a strong...
Ny berättelse • Mar 31
DANYELZA And Radiopharmaceuticals Realignment Will Energize Global Opportunities
Strategic realignment into DANYELZA and Radiopharmaceuticals could enhance revenue growth and operational efficiency through focused business units.Analysartikel • Mar 07
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders are probably feeling a little disappointed, since its shares...Seeking Alpha • Jan 24
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials
Summary YMAB's naxitamab sales declined from Q3 2023 to Q3 2024, but the company has a strong cash runway, supporting operations until 2027. Upcoming data readouts for GD2-SADA in Q2 2025 are critical for assessing the viability of their radiotherapy platform, most notably concerns related to toxicity. Despite risks, YMAB's current market cap of $270 million may be a bargain if upcoming data provides a clear clinical direction. I reiterate a "Buy" sentiment, with reservations about naxitamab sales growth and the uncertain future of GD2-SADA. Read the full article on Seeking AlphaAnalysartikel • Jan 10
Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet
To the annoyance of some shareholders, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares are down a considerable 26% in...Analysartikel • Dec 10
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysartikel • Nov 19
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders that were waiting for something to happen have been dealt a blow...Seeking Alpha • Oct 21
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
Summary Y-mAbs Therapeutics' naxitamab is approved for R/R High-Risk Neuroblastoma, with ongoing trials to expand its use, but the market size is limited. Financially, YMAB has a market cap of $644 million and a cash runway of 4-5 quarters, raising concerns about its ability to fund future R&D. The company is focusing on the SADA platform, but the lack of efficacy data makes it a speculative investment at this stage. Despite promising prospects, YMAB's low cash reserves and small market potential for naxitamab warrant a cautious investment approach. Read the full article on Seeking AlphaAnalysartikel • Sep 12
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares have had a really impressive month, gaining 33% after a shaky period...Seeking Alpha • Aug 12
Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Summary YMAB maintains a market valuation around $500 million, potential for substantial appreciation. Pipeline updates include expanding the naxitamab market and progressing SADA radioimmunotherapeutic. Financially, YMAB has $77.8 million in cash, growing product revenues, and a cash runway of 8-9 quarters. Read the full article on Seeking AlphaAnalysartikel • Jul 15
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analysartikel • Jun 02
Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%
The Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • May 09
Y-mAbs: There's A Ceiling Here Somewhere
Summary Y-mAbs Therapeutics has experienced a significant recovery in value but lacks upcoming catalysts for near-term growth. Their approved therapy, naxitamab, has shown promising results in treating pediatric cancers. Y-mAbs' GD2-SADA pipeline project has potential but carries high risk, and the company's financials are stable for now. Read the full article on Seeking AlphaAnalysartikel • Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Y-mAbs...Analysartikel • Feb 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares have continued their recent momentum with a 66% gain in the last month...Seeking Alpha • Jan 14
Y-mAbs Therapeutics: A Monoclonal Antibody Play
Summary Y-mAbs Therapeutics' shares have rebounded massively since March 2023 due to the company's restructuring, extending its cash runway until 2027. The company's main commercial asset is Danyelza, a monoclonal antibody for the treatment of neuroblastoma, which has shown promising sales. Y-mAbs is also evaluating Danyelza for other indications and has a novel cancer treatment program called SADA, but these are still in early stages. Chase the rally or time to take some profits? A full investment analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • Nov 13
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Y-mAbs Therapeutics tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 30 Jun 25 | 85 | -22 | 45 | 43 |
| 31 Mar 25 | 89 | -28 | 51 | 45 |
| 31 Dec 24 | 88 | -30 | 50 | 47 |
| 30 Sep 24 | 85 | -24 | 50 | 49 |
| 30 Jun 24 | 87 | -25 | 51 | 54 |
| 31 Mar 24 | 84 | -22 | 45 | 53 |
| 31 Dec 23 | 85 | -21 | 45 | 50 |
| 30 Sep 23 | 93 | -19 | 44 | 56 |
| 30 Jun 23 | 85 | -39 | 48 | 62 |
| 31 Mar 23 | 75 | -74 | 50 | 76 |
| 31 Dec 22 | 65 | -96 | 52 | 89 |
| 30 Sep 22 | 43 | -134 | 57 | 98 |
| 30 Jun 22 | 40 | -135 | 57 | 99 |
| 31 Mar 22 | 40 | -117 | 58 | 92 |
| 31 Dec 21 | 35 | -55 | 57 | 91 |
| 30 Sep 21 | 46 | -38 | 56 | 86 |
| 30 Jun 21 | 37 | -42 | 54 | 84 |
| 31 Mar 21 | 26 | -60 | 50 | 95 |
| 31 Dec 20 | 21 | -119 | 46 | 93 |
| 30 Sep 20 | 0 | -123 | 38 | 86 |
| 30 Jun 20 | 0 | -114 | 31 | 85 |
| 31 Mar 20 | 0 | -91 | 24 | 69 |
| 31 Dec 19 | 0 | -81 | 20 | 63 |
| 30 Sep 19 | 0 | -72 | 16 | 57 |
| 30 Jun 19 | 0 | -59 | 14 | 47 |
| 31 Mar 19 | 0 | -52 | 12 | 40 |
| 31 Dec 18 | 0 | -43 | 9 | 34 |
| 30 Sep 18 | 0 | -38 | 9 | 30 |
| 30 Jun 18 | 0 | -31 | 7 | 24 |
| 31 Mar 18 | 0 | -24 | 5 | 18 |
| 31 Dec 17 | 0 | -19 | 5 | 14 |
Kvalitetsintäkter: YMAB är för närvarande olönsam.
Växande vinstmarginal: YMAB är för närvarande olönsam.
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: YMAB är olönsam, men har minskat förlusterna under de senaste 5 åren med en hastighet av 29.4% per år.
Accelererande tillväxt: Det går inte att jämföra YMAB s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt
Resultat vs industri: YMAB är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Biotechs branschen ( 54.5% ).
Avkastning på eget kapital
Hög ROE: YMAB har en negativ avkastning på eget kapital ( -25.4% ), eftersom det för närvarande är olönsamt.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2025/09/15 19:53 |
| Aktiekurs vid dagens slut | 2025/09/15 00:00 |
| Intäkter | 2025/06/30 |
| Årlig intjäning | 2024/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Y-mAbs Therapeutics, Inc. bevakas av 8 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Peter Lawson | Barclays |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Thomas Shrader | BTIG |